Dirk Brockstedt
Hoofd Techniek/Wetenschap/O&O bij RAPT THERAPEUTICS, INC.
Vermogen: 216 996 $ op 30-04-2024
Actieve functies van Dirk Brockstedt
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
RAPT THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-06-2019 | - |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | Consultant / Adviseur | - | - |
Loopbaan van Dirk Brockstedt
Eerdere bekende functies van Dirk Brockstedt
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
CHINOOK THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-04-2009 | 01-12-2017 |
Anza Therapeutics, Inc.
Anza Therapeutics, Inc. Medical SpecialtiesHealth Technology Anza Therapeutics, Inc. develops products in the fields of cancer and infectious diseases. It also develops immunotherapy for infectious diseases, therapeutic vaccines for treating cancers that over-express Mesothelin and for treating people infected with the hepatitis C virus (HCV). The company was founded in 2007 and is headquartered in Concord, CA. | Hoofd Techniek/Wetenschap/O&O | 01-01-2007 | 01-01-2009 |
CERUS CORPORATION | Corporate Officer/Principal | 01-01-2002 | 01-01-2007 |
Aventis, Inc. | Corporate Officer/Principal | - | - |
Opleiding van Dirk Brockstedt
University of Kiel | Doctorate Degree |
Statistieken
Internationaal
Verenigde Staten | 7 |
Duitsland | 2 |
Operationeel
Chief Tech/Sci/R&D Officer | 3 |
Corporate Officer/Principal | 2 |
Doctorate Degree | 1 |
Sectoraal
Health Technology | 5 |
Consumer Services | 2 |
Finance | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
CERUS CORPORATION | Health Technology |
RAPT THERAPEUTICS, INC. | Health Technology |
Bedrijven in privébezit | 4 |
---|---|
Aduro BioTech, Inc.
Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
Aventis, Inc. | |
Anza Therapeutics, Inc.
Anza Therapeutics, Inc. Medical SpecialtiesHealth Technology Anza Therapeutics, Inc. develops products in the fields of cancer and infectious diseases. It also develops immunotherapy for infectious diseases, therapeutic vaccines for treating cancers that over-express Mesothelin and for treating people infected with the hepatitis C virus (HCV). The company was founded in 2007 and is headquartered in Concord, CA. | Health Technology |
ShangPharma Innovation, Inc.
ShangPharma Innovation, Inc. Investment ManagersFinance ShangPharma Innovation Inc. (ShangPharma Innovation) is a venture capital firm, a subsidiary of Shangpharma Investment Group Ltd. founded in 2016. The firm is headquartered in San Francisco, California. | Finance |
- Beurs
- Insiders
- Dirk Brockstedt
- Ervaring